84 results about "Beta-Adrenergic Agonist" patented technology

Provided is class of sodium channel blockers. One example of such a compound is shown by the following formula:The compounds are useful for promoting hydration of mucosal surfaces and treating a variety of disease conditions.

The present invention relates to new beta-agonists of general formula 1: wherein the groups R<1 >to R<12 >have the meanings given in the claims and specification, the isomers thereof, processes for preparing these compounds and their use as pharmaceutical compositions.

New chemical entities which comprise corticosteroids and phosphorylated β-agonists for use in therapy and compositions comprising and processes for preparing the same.

The present invention discloses a compound represented by formula (I), or an optical isomer, a pharmaceutically acceptable salt, a prodrug, a hydrate or a solvate thereof. In the formula (I), R1-R10 are respectively and independently selected from H, D, and are not all H. Compared with a non-deuterated control compound MGL3196, the compound or the optical isomer, the pharmaceutically acceptable salt, the prodrug, the hydrate or the solvate of the compound provided by the invention have the advantages that the agonistic activity on thyroid hormone receptor beta (THR-beta) is better; half-life period is longer, clearance rate is higher, metabolic stability and pharmacokinetic properties are better, and the application prospect in preparation method of THR-beta agonists, and medicines used for treating THR-beta agonist adaptation diseases including dyslipidemia, hypercholesterolemia, non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) is promising.

The present invention relates to new beta-agonists of general formula (I) wherein the groups R1 to R4 have the meanings given in ths claims and specification, the tautomers, racemates, enantiomers, diastereomers, solvates, hydrates, mixtures thereof, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, methods of preparing these compounds and their use as pharmaceutical compositions.

A mutual prodrug of a corticosteroid and a substituted phenylphosphate (ss-agonist derivative) for formulation for delivery by aerosolization to inhibit pulmonary inflammation and bronchoconstriction is described. The mutual prodrug is preferably formulated in a small volume solution (10-500 L) dissolved in a quarter normal saline having pH between 5.0 and 7.0 for the treatment of respiratory tract inflammation and bronchoconstriction by an aerosol having mass median average diameter predominantly between 1 to 5 , produced by nebulization or by dry powder inhaler.

The present invention relates to new beta-agonists of general formula (I) wherein the groups R1 to R4 have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers, solvates, hydrates, mixtures thereof, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, methods of preparing these compounds and their use as pharmaceutical compositions.

The present invention relates to new beta-agonists of general formula (I) wherein the groups R1 and R2 have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers, solvates, hydrates, mixtures thereof, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, methods of preparing these compounds and their use as pharmaceutical compositions.